BeOne Medicines Ltd. 4

SVP & General Counsel Lee Chan Henry exercised options into 664 ADSs of BeOne Medicines Ltd. and sold all 664 ADSs on 2026-07-08 for roughly $201K while retaining 338,884 ordinary shares.

On July 8, 2026, BeOne Medicines Ltd. SVP and General Counsel Lee Chan Henry exercised multiple employee stock options for a total of 8,632 ordinary shares (2,626 at a 14.96 ordinary-share equivalent, 3,458 at 16.41, and 2,548 at 12.23, each option denominated in ordinary shares and zero-priced in the Form 4 summary) that converted into American Depositary Shares (ADSs), each ADS representing 13 ordinary shares. The exercises produced 664 ADSs (8,632 ÷ 13) which were then fully sold the same day in a single Rule 10b5‑1 planned trade at $302.46 per ADS for gross proceeds of approximately $200,833, leaving the reporting person with no ADS position reported under the derivative transaction line but 338,884 ordinary shares still held directly. Based on the sale price of $302.46 per ADS (or roughly $23.27 per ordinary share), the remaining 338,884 ordinary shares represent an estimated post-transaction holding value of about $7.9 million, indicating this was a relatively small, pre‑planned liquidity event compared to the insider’s retained stake.

Filing Facts

CIK

1651308

Ticker

ONC

Form

4

Source Type

fda

Accession

0001980648-26-000017

Alert Tier

6